GDUFA II: More Than 2,000 ANDAs Remain Unclaimed, Large Firms Still Dominate
Executive Summary
Firms could find themselves charged multiple US generic drug user fees if affiliates are not identified and ANDAs claimed.
You may also be interested in...
Unhappy With GDUFA II? Note It For GDUFA III, FDA Says
US agency says it is implementing generic drug user fee program as outlined in commitment letter and any changes should be discussed at negotiations for the 2022 renewal.
Unhappy With GDUFA II? Note It For GDUFA III, FDA Says
US agency says it is implementing generic drug user fee program as outlined in commitment letter and any changes should be discussed at negotiations for the 2022 renewal.
Generic Industry Consolidating But Still Mysterious
Nearly 2,000 ANDAs remain unclaimed as US FDA begins fee calculations for GDUFA II.